Read "Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop" at NAP.edu

Page 115 Cite Bookmark

Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.

Appendix A

Workshop Agenda

ADULT ATTENTION-DEFICIT/HYPERACTIVITY DISORDER:
DIAGNOSIS, TREATMENT, AND IMPLICATIONS FOR DRUG DEVELOPMENT—A WORKSHOP

Keck Center, 500 Fifth St. NW
Washington DC, 20001

DAY 1: TUESDAY, DECEMBER 12, 2023

9:00 am	WELCOME, OPENING REMARKS, AND SETTING THE STAGE
	CRAIG B.H. SURMAN, Workshop Co-chair Director, Clinical and Research Program in Adult ADHD Massachusetts General Hospital Associate Professor of Psychiatry Harvard Medical School
9:35 am	REGULATORY OVERVIEW
9:35 am	MARTA SOKOLOWSKA Deputy Center Director Substance Use and Behavioral Health Center for Drug Evaluation and Research U.S. Food and Drug Administration

Page 116 Cite Bookmark

Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.

SESSION I—DIAGNOSIS OF ADULTS WITH ADHD

Session Objectives:

Discuss the criteria and available tools for diagnosis of ADHD in adults (including DSM-5 criteria, assessment tools, best practices in diagnosing the condition);
Explore gaps and barriers when it comes to appropriate diagnosis of ADHD for different adult populations; and
Consider the long-term public health implications of under-diagnosing, differential diagnosing, and misdiagnosing ADHD in adults and considerations for different populations.

9:55 am	Presentation
9:55 am	ANN CHILDRESS President Center for Psychiatry and Behavioral Medicine, Inc. President The American Professional Society for ADHD and Related Disorders
10:20 am	Panel Discussion
	Moderator: Steve Lee, University of California, Los Angeles
	Clinical Diagnosis Perspective NAPOLEON HIGGINS President and Chief Executive Officer Bay Pointe Behavioral Health
	Clinical Screening Perspective SARA L. WEISENBACH Associate Professor of Psychology in Psychiatry, Harvard Medical School President, American Psychological Association, Society for Clinical Neuropsychology (Division 40) Chief of Neuropsychology McLean Hospital
	Lived Experience Perspective TAMARA ROSIER Owner, ADHD Center of West Michigan President ADHD Coaches Organization

Page 117 Cite Bookmark

Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.

Research Perspective

MARGARET SIBLEY

Professor of Psychiatry and Behavioral Sciences

University of Washington School of Medicine

Discussion Questions:

Why do clinicians find it challenging to diagnose ADHD in adults (e.g., co-morbidities, differential diagnosis with other conditions such as depression, anxiety, other psychiatric conditions, and/or COVID-19)?
What barriers do adults experience when seeking a diagnosis of ADHD, particularly those from minority and medically underserved communities?
How does an ADHD diagnosis, or the lack of one, impact individuals across adulthood?
How is ADHD diagnosed under the DSM 5 criteria?

11:20 am

Coffee Break

SESSION II—MEDICATION OPTIONS FOR ADULTS WITH ADHD: RISKS AND BENEFITS

Session Objectives:

Consider what is known and unknown about the risks and benefits of ADHD medication use in adult populations;
Consider the public health implications for potential overprescribing of Schedule II stimulants;
Discuss the barriers (e.g., legal, regulatory, social, cultural) to access of equitable treatment for adults with ADHD; and
Explore approaches for alternative treatment options for adults with ADHD (e.g., non-pharmacological interventions, re-tooling of existing medications, new drug development) that may reduce the risk of harm to patients, that take into account social and cultural considerations.

11:50 am

Presentation

DAVID W. GOODMAN

Assistant Professor of Psychiatry and Behavioral Sciences

Johns Hopkins University School of Medicine

Page 118 Cite Bookmark

Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.

12:10 pm	Panel Discussion
	Moderator: James (Jimmy) Leonard, Maryland Poison Center; University of Maryland School of Pharmacy
	Lived Experience Perspective DUANE GORDON President Attention Deficit Disorder Association
	Clinical/Pharmacology Perspective (Medication Treatments) ANGELA MAHOME Staff Psychiatrist The University of Chicago
	Research/Clinical Perspective (Nonmedication Treatments/CBT) J. RUSSELL RAMSAY Independent Practice Former Co-Founder, Co-Director, Adult ADHD Treatment and Research Program University of Pennsylvania
	Regulatory Perspective TIFFANY R. FARCHIONE Director, Division of Psychiatry Center for Drug Evaluation and Research, FDA
	Discussion Questions: What is known and unknown about the risks and benefits of medication (stimulant and non-stimulant) use for the treatment of ADHD in adult populations? What are the primary barriers (e.g., legal, regulatory, social, cultural) to appropriate treatment for adults with ADHD and how have these barriers been overcome? What are the health equity implications of these approaches? How can prescribers, clinicians, and other providers be better informed regarding the treatment options available to their patients?
1:10 pm	Lunch Break

Page 119 Cite Bookmark

Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.

SESSION III—IMPLICATIONS FOR DRUG DEVELOPMENT

Session Objectives:

Consider areas of unmet treatment needs for adults with ADHD that could potentially be addressed through new and/or improved therapeutics; and
Explore challenges and opportunities for the development of new and improved therapeutics for the treatment of ADHD, including options that may reduce the risk of diversion.

2:00 pm	Presentation
2:00 pm	CRAIG BERRIDGE The Patricia Goldman-Rakic Professor of Psychology University of Wisconsin, Madison
2:20 pm	Panel Discussion
	Moderator: Stevin Zorn, MindImmune Therapeutics, Inc.
	Industry Perspective JONATHAN RUBIN Chief Medical Officer and Senior Vice President of Research & Development Supernus Pharmaceuticals
	Neurobiology/Pharmacology Perspective AMY ARNSTEN Albert E. Kent Professor of Neuroscience and Professor of Psychology Yale School of Medicine
	Regulatory Perspective ERIKA LIETZAN William H. Pittman Professor of Law & Timothy J. Heinsz Professor of Law University of Missouri School of Law
	Discussion Questions: How do available therapeutic treatment options meet the needs of adults with ADHD? What are the gaps/unmet medical needs?

Page 120 Cite Bookmark

Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.

	How might alternative treatment options for adults with ADHD reduce the risk of harms, such as misuse potential, overdose, and toxicity? What are the barriers and opportunities to the development of new medications for treating adults with ADHD?
3:20 pm	Coffee Break

SESSION IV—DAY 1 SYNTHESIS AND DISCUSSION

Session Objectives:

Discuss key themes from previous workshop sessions;
Lay out questions to be addressed; and
Consider next step opportunities for improving the diagnosis and treatment of adults with ADHD; implications for drug development.

3:50 pm	Panel Discussion
	Moderator: Craig B. H. Surman, Massachusetts General Hospital; Harvard Medical School
	Pharmacology Perspective ALMUT WINTERSTEIN Director, Center for Drug Evaluation and Safety (CoDES) and Consortium for Medical Marijuana Clinical Outcomes Research Distinguished Professor, Pharmaceutical Outcomes and Policy University of Florida
	Industry Perspective DAVID BAKER Former Pharmaceutical Executive – Shire, Alcobra, Vallon Pharmaceuticals Board Member Edge Foundation
	Lived Experience Perspective KOFI OBENG Executive Director Attention Deficit Disorder Association

Page 121 Cite Bookmark

Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.

	Resources and Education Perspective SUNNY PATEL Senior Advisor for Children, Youth and Families SAMHSA
	Research Perspective MARY SOLANTO Professor of Pediatrics and Psychiatry Zucker School of Medicine at Hofstra-Northwell
	Discussion Questions: Based on the day’s sessions, what are the main themes you heard regarding the diagnosis, treatment, and drug development for ADHD in adult populations? What questions remain? How can the use of a health equity framework help the those with adult ADHD, health professionals, and others better understand the social, political, economic, and environmental factors impacting the diagnosis and treatment of adult ADHD? How do we bridge the gap from where we are now to where we want to be? What is needed and from whom? What are some key things from today’s sessions we should keep in mind as we move into Day 2?
4:35 pm	Audience Q&A
	DAY 1 CLOSING REMARKS
	CARLOS BLANCO, Workshop Co-chair Director, Division of Epidemiology, Services, and Prevention Research National Institute on Drug Abuse, NIH
5:00 pm	Adjourn Workshop Day 1
5:00 pm	Reception

Page 122 Cite Bookmark

Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.

DAY 2: WEDNESDAY, DECEMBER 13, 2023

8:30 am	OPENING REMARKS
8:30 am	CARLOS BLANCO, Workshop Co-chair Director, Division of Epidemiology, Services, and Prevention Research National Institute on Drug Abuse, NIH
8:40 am	FIRESIDE CHAT
	CARLOS BLANCO, Workshop Co-chair Director, Division of Epidemiology, Services, and Prevention Research National Institute on Drug Abuse, NIH
	EVELYN POLK GREEN Immediate Past President; Attention Deficit Disorder Association Past President; Children & Adults with Attention Deficit/Hyperactivity Disorder

SESSION V—ENABLING ACCESS TO RESOURCES AND SHARED DECISION MAKING FOR ADULTS WITH ADHD AND THEIR PROVIDERS

Session Objective:

Share perspectives and available resources for prescribers, clinicians, and patients on the risks and benefits of ADHD medication use in adults, particularly for underserved populations;
Discuss practical approaches that have helped overcome barriers (e.g., stigma, misdiagnosis) to appropriate diagnosis and treatment of adults with ADHD; and
Consider opportunities to enable shared decision making between patients and their providers regarding the diagnosis and treatment of ADHD.

9:20 am

Presentation

MARK OLFSON

Professor of Psychiatry, Medicine, and Law;

Professor of Epidemiology

Columbia University

Page 123 Cite Bookmark

Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.

9:40 am	Presentation
9:40 am	LARA ROBINSON Behavioral Scientist National Center on Birth Defects and Developmental Disabilities, CDC
9:55 am	Panel Discussion
	Moderator: Andrea Chronis-Tuscano, University of Maryland, Department of Psychology
	Lived Experience Perspective KYLIE BARRON
	Clinical Perspective BRANDI WALKER Chief Executive Officer Marie Pauline Consulting, LLC
	Psychiatrist Perspective BENJAMIN CHEYETTE Psychiatrist Director of ADHD Programming Mindful Health Solutions
	Telehealth and Social Media Perspective JESSICA GOLD Associate Professor, Department of Psychiatry, University of Tennessee Health and Science Center Chief Wellness Officer University of Tennessee (UT) System (As of 2/1/2024)
	Discussion Questions: What methods and/or systems are in place to support prescribers, clinicians, and other providers who diagnose and treat adults with ADHD? What else is needed? Are there lessons learned from the diagnosis and treatment of pediatric populations that may be applicable for adult populations?

Page 124 Cite Bookmark

Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.

What approaches have and/or could help support adults with ADHD make informed decisions about the risks and benefits of ADHD medication use?
How can we best disseminate evidence-based educational materials/content about adult ADHD to patients (including those from diverse backgrounds) so that they can engage in informed discussions around their care?

SESSION VI—PUBLIC HEALTH CONSIDERATIONS AND HARM REDUCTION STRATEGIES FOR ADHD MEDICATION USE

Session Objectives:

Share perspectives on the causes, perceptions, consequences, and health equity implications of non-medical use of prescription stimulants;
Discuss what is known and unknown about the intersection of ADHD medication use (medical and non-medical) and opioid use; and
Consider how strategies to reduce the misuse of ADHD medications could impact public health (e.g., limiting patient access to medication, exacerbating existing health inequities).

10:55 am	Presentation
10:55 am	BROOKE MOLINA Professor of Psychiatry, Psychology, Pediatrics, Clinical & Translational Science University of Pittsburgh
11:15 am	Panel Discussion
	Moderator: Taleed El-Sabawi, Florida International University
	Clinical Perspective ROBIN WEISS Private Practice of Psychiatry Past President Maryland Psychiatric Society
	Lived Experience Perspective PATRICK KELLY

Page 125 Cite Bookmark

Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.

	Research/Community Health Perspective RYAN MCNEIL Associate Professor, Director of Harm Reduction Research Yale School of Medicine
	Research/Clinical Perspective KEVIN ANTSHEL Professor of Psychology and Associate Department Chair Syracuse University
	Discussion Questions: What is known and unknown about the intersection of ADHD medication use (medical and non-medical) and opioid use? What are public health and health equity implications of not appropriately treating adults with ADHD? What strategies (e.g., public health efforts, regulatory policies) have been deployed to reduce the misuse of ADHD medications and what was the impact on people with ADHD? What was the impact on public health?
12:15 pm	Coffee Break

SESSION VII—DAY 2 SYNTHESIS AND DISCUSSION

Session Objectives:

Discuss key themes from previous workshop sessions; and
Consider next step opportunities for improving the diagnosis and treatment of adults with ADHD.

12:45 pm	Panel Discussion
	Moderator: Carlos Blanco, National Institute on Drug Abuse, NIH
	Clinical Perspective—ADHD in underserved populations JOSEPH SCHATZ Director, Psychiatric/Mental Health Nurse Practitioner Track University of Pennsylvania School of Nursing
	Lived Experience Perspective TALEED EL-SABAWI Assistant Professor of Law Florida International University

Page 126 Cite Bookmark

Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.

	Pharmacology Perspective MATTHEW RUDORFER Chief, Psychopharmacology, Somatic, and Integrated Treatment Research Program National Institute of Mental Health, NIH
	Research Perspective AMELIA ARRIA Director, Center on Young Adult Health and Development Professor, Department of Behavioral and Community Health University of Maryland School of Public Health
	Family Medicine Perspective LATASHA SELIBY PERKINS Assistant Professor of Medicine Georgetown University School of Medicine
	Discussion Questions: Based on the day’s sessions, what are the main themes you heard regarding enabling access to resources, shared decision making, and strategies to reduce the misuse of ADHD medications for adults with ADHD? What questions remain? How can the use of a health equity framework help those with adult ADHD, health professionals, and others better understand the social, political, economic, and environmental factors impacting the health and overall well-being of adults with ADHD? Considering everything you’ve heard over the past day and a half, what is important for the FDA to know as it relates to diagnosis, treatment, and drug development for adult ADHD?
1:35 pm	Audience Q&A
1:50 pm	CLOSING REMARKS
1:50 pm	MARTA SOKOLOWSKA Deputy Center Director Substance Use and Behavioral Health Center for Drug Evaluation and Research U.S. Food and Drug Administration

Page 127 Cite Bookmark

Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.

CRAIG B.H. SURMAN, Workshop Co-chair

Director, Clinical and Research Program in Adult ADHD

Massachusetts General Hospital

Associate Professor of Psychiatry

Harvard Medical School

2:00 pm

Adjourn Day 2

Page 128 Cite Bookmark

Suggested Citation: "Appendix A: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27770.

This page intentionally left blank.

Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop (2024)

Chapter: Appendix A: Workshop Agenda

Appendix A

Workshop Agenda

ADULT ATTENTION-DEFICIT/HYPERACTIVITY DISORDER:
DIAGNOSIS, TREATMENT, AND IMPLICATIONS FOR DRUG DEVELOPMENT—A WORKSHOP

DAY 1: TUESDAY, DECEMBER 12, 2023

SESSION I—DIAGNOSIS OF ADULTS WITH ADHD

SESSION II—MEDICATION OPTIONS FOR ADULTS WITH ADHD: RISKS AND BENEFITS

SESSION III—IMPLICATIONS FOR DRUG DEVELOPMENT

SESSION IV—DAY 1 SYNTHESIS AND DISCUSSION

DAY 2: WEDNESDAY, DECEMBER 13, 2023

SESSION V—ENABLING ACCESS TO RESOURCES AND SHARED DECISION MAKING FOR ADULTS WITH ADHD AND THEIR PROVIDERS

SESSION VI—PUBLIC HEALTH CONSIDERATIONS AND HARM REDUCTION STRATEGIES FOR ADHD MEDICATION USE

SESSION VII—DAY 2 SYNTHESIS AND DISCUSSION

My Academies

Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop (2024)

Chapter: Appendix A: Workshop Agenda

Appendix A Workshop Agenda

ADULT ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: DIAGNOSIS, TREATMENT, AND IMPLICATIONS FOR DRUG DEVELOPMENT—A WORKSHOP

DAY 1: TUESDAY, DECEMBER 12, 2023

SESSION I—DIAGNOSIS OF ADULTS WITH ADHD

SESSION II—MEDICATION OPTIONS FOR ADULTS WITH ADHD: RISKS AND BENEFITS

SESSION III—IMPLICATIONS FOR DRUG DEVELOPMENT

SESSION IV—DAY 1 SYNTHESIS AND DISCUSSION

DAY 2: WEDNESDAY, DECEMBER 13, 2023

SESSION V—ENABLING ACCESS TO RESOURCES AND SHARED DECISION MAKING FOR ADULTS WITH ADHD AND THEIR PROVIDERS

SESSION VI—PUBLIC HEALTH CONSIDERATIONS AND HARM REDUCTION STRATEGIES FOR ADHD MEDICATION USE

SESSION VII—DAY 2 SYNTHESIS AND DISCUSSION

Appendix A

Workshop Agenda

ADULT ATTENTION-DEFICIT/HYPERACTIVITY DISORDER:
DIAGNOSIS, TREATMENT, AND IMPLICATIONS FOR DRUG DEVELOPMENT—A WORKSHOP